For the quarter ending 2025-12-31, OTLK made -$1,207,833 in revenue. -$23,058,135 in net income. Net profit margin of 1909.05%.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Revenues, net | -1,207,833 | -3,102,431* | 1,505,322 | |
| Cost of revenues | 29,626 | 36,885* | 439,815 | |
| Gross profit | -1,237,459 | -3,139,316* | 1,065,507 | |
| Research and development | 3,634,352 | 5,776,522* | 7,134,706 | |
| Selling, general and administrative | 8,612,141 | 10,899,788* | 9,679,481 | |
| Loss from operations | -13,483,952 | -19,815,626* | -15,748,680 | |
| Loss on equity method investment | -38,634 | -48,355* | -30,884 | |
| Interest income | - | 22,434.5* | - | |
| Interest income | 0 | -135,075* | -49,351 | |
| Gain from change in fair value of promissory notes | 6,743,736 | -897,345* | 2,323,977 | |
| Warrant inducement expenses (note 10) | - | 8,380,468.5* | - | |
| Loss (gain) from change in fair value of warrant liability | 2,791,813 | -25,104,430.75* | 1,999,610 | |
| Loss before income taxes | - | -2,355,314.25* | -20,152,502 | |
| Income tax (benefit) expense | - | -387,957.25* | - | |
| Net (loss) income | -23,058,135 | -1,967,357 | -20,152,502 | |
| Basic EPS | -0.38 | -0.06 | -0.55 | |
| Diluted EPS | -0.38 | -0.06 | -0.55 | |
| Basic Average Shares | 60,205,035 | 32,635,658 | 36,956,582 | |
| Diluted Average Shares | 60,205,035 | 32,635,658 | 36,956,582 | |
Outlook Therapeutics, Inc. (OTLK)
Outlook Therapeutics, Inc. (OTLK)